Stay updated with breaking news from Abivax. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today reports... | March 10, 2022
Out of the 40 patients who enrolled into the ABX464 maintenance study, 23 patients have now reached the first year of treatment and all achieved at least an ACR20 [1] , with 19 and 12 patients achieving
Abivax will be hosting a Satellite Symposium on February 17, 2022, at 12:00-1:00 pm CET (6:00-7:00am ET) on ABX464's potential to address unmet medical needs for the treatment of ulcerative colitis (UC)Presentations
ABX196 phase 1/2 study results for the treatment of hepatocellular carcinoma (HCC) were selected for a presentation at the ASCO Gastrointestinal Cancers Symposium 2022ABX196 at a maximum dose of 0.4µg
19.01.2022 - DGAP-News: ABIVAX / Key word(s): Study results/Conference Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022 19.01.2022 / 08:00 The issuer is solely responsible for ... Seite 1